2000 International AIDS Conference

2000 International AIDS Conference
Name	2000 International AIDS Conference
Date	7–12 August 2000
Location	Durban, South Africa
Venue	Durban International Convention Centre
Participants	Tens of thousands
Organized by	International AIDS Society
Preceding	1998 International AIDS Conference
Following	2002 International AIDS Conference

2000 International AIDS Conference was the 13th quadrennial global gathering addressing HIV/AIDS and was held in Durban, KwaZulu-Natal from 7 to 12 August 2000, organized by the International AIDS Society, the South African Medical Research Council, and multiple international health institutions. The conference assembled researchers, policymakers, activists, clinicians, representatives from World Health Organization, UNAIDS, pharmaceutical companies such as GlaxoSmithKline and Merck & Co., and civil society delegates from Médecins Sans Frontières, Treatment Action Campaign, and regional networks across Africa, Asia, and the Americas.

Background and planning

The choice of Durban followed lobbying by African health authorities including the South African National AIDS Council and advocacy by activists associated with Treatment Action Campaign, Health GAP, and the AIDS Law Project, countering proposals from delegations from Geneva, London, New York City, and Boston. Preparatory meetings involved the International AIDS Society, UNAIDS, the World Bank, and funders such as the Bill & Melinda Gates Foundation and the Global Fund to Fight AIDS, Tuberculosis and Malaria; public health researchers from Harvard University, University of Cape Town, University of Oxford, and University of California, San Francisco contributed to programme design. Logistical coordination required cooperation among the KwaZulu-Natal Department of Health, Durban Municipality, South African Department of Health, local universities, and international NGOs including Oxfam, CARE International, and Population Services International.

Conference programme and sessions

Plenary sessions featured panels from World Health Organization Director-General candidates, UNAIDS Executive Directors, and leading investigators from Centers for Disease Control and Prevention and National Institutes of Health, alongside moderated sessions led by scholars from Columbia University, Imperial College London, Johns Hopkins University, and Stellenbosch University. The scientific programme included presentations on antiretroviral therapy efficacy from trials conducted by groups at University of Pennsylvania, Fred Hutchinson Cancer Research Center, and Karolinska Institutet, epidemiological modelling workshops involving researchers from Imperial College London, London School of Hygiene & Tropical Medicine, and Institut Pasteur, and implementation panels with representatives from Médecins Sans Frontières, Partners In Health, and ActionAid. Satellite symposia hosted by GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, and academic consortia discussed drug access, while community forums organized by International Community of Women Living with HIV/AIDS, People Living with HIV Stigma Network, and youth delegations from UNICEF addressed human rights, stigma, and gender-based programming.

Key participants and speakers

Key political figures included Nelson Mandela, who sent messages of support, and delegates from the South African Government and provincial leaders from KwaZulu-Natal and Western Cape; international policymakers included representatives from the United States Department of State, European Commission, and the African Union. Scientific speakers featured investigators such as Françoise Barré-Sinoussi, Robert Gallo, and representatives from Peter Piot's teams; clinical trialists from Merck Research Laboratories and Glaxo Wellcome presented data alongside public health leaders from UNAIDS and World Health Organization. Activist speakers included leaders from Treatment Action Campaign, AIDS Coalition to Unleash Power (ACT UP), Southern Africa Litigation Centre, and Global Network of People Living with HIV, while philanthropic voices came from the Bill & Melinda Gates Foundation and corporate social responsibility delegations from multinational firms including Pfizer and Roche.

Major announcements and policy impacts

Sessions announced expanded commitments to antiretroviral rollout programs, catalyzing later policy instruments such as the Global Fund to Fight AIDS, Tuberculosis and Malaria financing rounds and influencing national treatment plans in South Africa, Brazil, and Thailand. Scientific disclosures included trial results influencing the adoption of combination antiretroviral therapy regimens promoted by World Health Organization treatment guidelines and programs financed by World Bank initiatives. The conference shaped negotiations that fed into the Doha Declaration on the TRIPS Agreement and Public Health debates, informing compulsory licensing discussions in countries including India, Brazil, and South Africa and affecting patent policy dialogues with multinational corporations such as Novartis and Bayer.

Controversies and protests

The conference saw intense protests by activists from Treatment Action Campaign, Médecins Sans Frontières, ACT UP, and community coalitions over issues including access to medicines, pricing by pharmaceutical companies such as GlaxoSmithKline and Bristol-Myers Squibb, and the South African Department of Health's policies. Public disputes involved prominent figures like Manto Tshabalala-Msimang in later policy debates and generated demonstrations coordinated with trade union allies from Congress of South African Trade Unions and student groups from University of the Witwatersrand and University of Natal. Contentious panels addressed science-policy clashes featuring critics of governmental positions and representatives from intellectual property advocacy groups and human rights organizations such as Amnesty International.

Legacy and subsequent developments

The conference is credited with accelerating global scale-up of antiretroviral therapy, influencing programs by UNAIDS, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and bilateral initiatives like the President's Emergency Plan for AIDS Relief; it also energized litigation and policy campaigns involving the South African Constitutional Court and international negotiations at World Trade Organization meetings. Research agendas at institutions including Harvard School of Public Health, University of Cape Town Faculty of Health Sciences, and London School of Hygiene & Tropical Medicine shifted toward implementation science, while activist networks such as Treatment Action Campaign and Médecins Sans Frontières expanded global advocacy that led to subsequent conferences in Barcelona (2002) and affected the trajectories of vaccine research at centers like Pasteur Institute and National Institute of Allergy and Infectious Diseases. The Durban meeting remains a focal point in histories of HIV/AIDS activism and public health policy in the early 21st century.

Category:International AIDS Conferences Category:HIV/AIDS in South Africa Category:2000 conferences